Emmanuel “Chip” Walter Jr.
Professor of Pediatrics
Affiliate, Duke Global Health Institute
Appointment:
Topics:
Countries:
Emmanuel “Chip” Walter Jr.
Professor of Pediatrics
Affiliate, Duke Global Health Institute
Dr. Emmanuel Walter, MD, MPH, Professor of Pediatrics, serves as the Duke Human Vaccine Institute (DHVI) Chief Medical Officer and directs the Duke Vaccine and Trials Unit. In these roles, Dr. Walter provides strategic and operational leadership for clinical research conducted at the Institute. In addition, he provides oversight of regulatory compliance for DHVI clinical research activities.
Dr. Walter has dedicated his career to advancing research and clinical practice in vaccinology, infectious diseases, and child health. He currently serves as the principal investigator for the Duke Clinical Core of the Collaborative Influenza Vaccine Innovations Centers (CIVICs) funded by the National Institute of Allergy and Infectious Diseases (NIAID). The goal of this work is to evaluate promising next generation influenza vaccine candidates in Phase I and Phase I/II clinical trials and human challenge studies. He is the Duke Co-Principal Investigator for the NIAID Vaccine and Treatment Evaluation Unit (VTEU) which conducts clinical trials of vaccines and treatments for infectious diseases. He is also the Duke Principal Investigator for the CDC-funded Clinical Immunization Safety Assessment Project which conducts studies to identify risk factors and preventive strategies for adverse events following immunization, particularly in special populations. Lastly, he is the Principal Investigator for a CDC-funded project to further understand and reduce disparities in vaccine coverage among rural adolescents.
Dr. Walter's focused area of interest include vaccine development, vaccine safety, vaccine coverage, prevention and treatment of infectious diseases.
Publications
-
Chung JR, Price AM, House SL, Mills J, Wernli KJ, Sanchez M, et al. Influenza vaccine effectiveness against outpatient acute respiratory illness with laboratory-confirmed influenza, United States, 2024-25 season. medRxiv. 2026 Mar 26;Heng F, Magaret CA, Rouphael NG, Branche AR, Fong Y, Carpp LN, et al. The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distances. Vaccine. 2026 Mar 19;76:128348.Biddle JE, House S, Kwon JH, Presti RM, Fritz SA, Curley T, et al. Estimating influenza transmission parameters: Comparing two study designs, 2023-2024. Epidemics. 2026 Mar;54:100888.Smith MJ, Harrington TA, Chung RJ, Rountree W, Poniewierski MS, Spreng RL, et al. Preventing Postvaccination Presyncope and Syncope in Adolescents: A Randomized Controlled Trial of a Clinic-Based Intervention. J Pediatr. 2026 Feb 13;293:115035.
See more publications at Scholars@Duke